Drug Profile
BCI 202
Alternative Names: BCI-201Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Vitamin D analogues
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 29 Mar 2011 Discontinued - Preclinical for Psoriasis in USA (PO)
- 30 Jun 2005 Bone Care International has been acquired and merged into Genzyme Corporation
- 27 Mar 2001 Preclinical development for Psoriasis in USA (PO)